Myriad Genetics (MYGN) announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad’s ability to bring its tumor-informed, high-definition, ...
TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...
New Delhi [India] / London [UK] / Munich [Germany], January 28: Datar Cancer Genetics (DCG) has launched a revolutionary video-reporting service for in-vitro chemosensitivity testing, powered by ...
NEW DELHI and LONDON and MUNICH, Jan. 28, 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG) has launched a revolutionary video-reporting service for in-vitro chemosensitivity testing, powered by AI ...
Datar Cancer Genetics (DCG) today announced the launch of Target-MRD, an advanced molecular residual disease (MRD) monitoring blood test for solid ...
The test evaluates the effectiveness or resistance of chemotherapy drugs through direct observation of their action on tumor cells. It personalizes treatment ...
-Datar Cancer Genetics presenta un revolucionario análisis de sangre informado basado en el tumor para el control de enfermedades residuales El análisis de sangre Target-MRD utiliza una ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback